This is the authors' abstract. We don't add key points for this paper.
poses significant health risks through its virulent peptide toxin Candidalysin. As no existing therapeutics specifically target this toxin, developing high-affinity aptamers for its efficient and safe removal is urgently needed. In response, we developed a dual-mode biosensor based on gold nanoparticles (AuNPs) and aptamers for screening high-affinity aptamers for Candidalysin. This biosensor leverages the localized surface plasmon resonance (LSPR) phenomenon and surface-enhanced Raman scattering (SERS) of AuNPs to detect changes in color and Raman signals, respectively, indicative of high-affinity aptamer for Candidalysin presence. This dual-mode capability reduces false-negative signals and enhances detection accuracy. Our findings reveal a specific aptamer with high affinity for Candidalysin, presenting a significant advancement in candidiasis treatment. This work sets the stage for the development of effective therapeutic strategies against Candida infections.
No takes yet. Share an insight, caveat, or question.
Sun et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: